
Yuval Itan, PhD
About Me
Dr. Yuval Itan is an Associate Professor in the Department of Genetics and Genomic Sciences, a core member of The Charles Bronfman Institute for Personalized Medicine, and a member of Mindich Child Health and Development Institute, at the Icahn School of Medicine at Mount Sinai in New York City.
The main focus of the Itan lab is investigating human disease genomics for enhancing precision medicine, by developing new machine learning and computational methods to detect disease-causing variants and genes in next generation sequencing data of patients, and by performing cases-controls genome- and phenome-wide studies of patient cohorts across diverse human populations to identify new genetic etiologies of human diseases.
The Itan lab applies and combines diverse approaches across computer science and biology, including machine learning, natural language processing, bioinformatics, statistical genomics, modelings and simulations, and population genetics.
Language
English
Position
ASSOCIATE PROFESSOR | Artificial Intelligence and Human Health, ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Research Topics
Bioinformatics, Biomedical Informatics, Biomedical Sciences, Biostatistics, Cardiovascular, Clinical Genomics, Computational Biology, Computer Simulation, Coronavirus, Epidemiology, Evolution, Gastroenterology, Gene Discovery, Genetics, Genomics, Immune Deficiency, Infectious Disease, Inflammatory Bowel Disease (IBD), Mathematical Modeling of Biomedical Systems, Mathematical and Computational Biology, Neural Networks, Obesity, Parkinson's Disease, Personalized Medicine, Proteomics, Sequence Alignment, Systems Biology, Technology & Innovation, Theoretical Biology, Translational Research
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Genetics and Genomic Sciences [GGS]
Education
BSc, Bar-Ilan University
PhD, University College London
Postdoc, The Rockefeller University
Research
Publications
Selected Publications
- Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2. Lili Hu, Renee M. van der Sluis, Kennith Brian Castelino, Bao Cun Zhang, Andreas Ronit, Thomas Zillinger, Marvin Werner, Sofie Eg Jørgensen, Anne Louise Hansen, Alice Pedersen, Ryo Narita, Line S. Reinert, Bettina Bundgaard, Marie Helleberg, Thomas Benfield, Merete Storgaard, Kristoffer Skaalum Hansen, Jacob Bodilsen, Shen Ying Zhang, Qian Zhang, Mayana Zatz, Joost Wauters, Horst von Bernuth, Donald C. Vinh, Fernanda Sales Luiz Vianna, Diederik van de Beek, Mohammed J. Uddin, K. M.Furkan Uddin, Stuart E. Turvey, Sophie Trouillet-Assant, Pierre Tiberghien, Christian Thorball, Şehime Gülsün Temel, Ahmad Abou Tayoun, Stuart G. Tangye, Ivan Tancevski, Helen C. Su, András N. Spaan, Vassili Soumelis, Pere Soler-Palacín, Andrew L. Snow, Ondrej Slaby, Anna Shcherbina, Mohammad Shahrooei, Mikko R.J. Seppänen, Anna Sediva, Vanessa Sancho-Shimizu, Carlos Rodríguez-Gallego, Yuval Itan, Dusan Bogunovic. Nature Communications
- Development of a genetic priority score to predict drug side effects using human genetic evidence. Áine Duffy, Robert Chen, David Stein, Joshua K. Park, Matthew Mort, Marie Verbanck, Avner Schlessinger, Yuval Itan, David N. Cooper, Daniel M. Jordan, Ghislain Rocheleau, Ron Do. Nature Communications
- Expanding the utility of variant effect predictions with phenotype-specific models. David Stein, Meltem Ece Kars, Baptiste Milisavljevic, Matthew Mort, Peter D. Stenson, Jean Laurent Casanova, David N. Cooper, Bertrand Boisson, Peng Zhang, Avner Schlessinger, Yuval Itan. Nature Communications